Water chemistry

Kane Biotech Expands its Wound Care and Surgical Portfolio with a coactiv+TM Antimicrobial Hydrogel

Retrieved on: 
Thursday, July 22, 2021
Gels, Colloidal chemistry, Hydrogel, Water chemistry, Natural sciences, Wound, Clinical medicine, Health sciences

WINNIPEG, Manitoba, July 22, 2021 (GLOBE NEWSWIRE) -- Kane Biotech Inc. announces plans to expand its wound care and surgical portfolio with an antimicrobial hydrogel based on its best-in-class coactiv+ technology.

Key Points: 
  • WINNIPEG, Manitoba, July 22, 2021 (GLOBE NEWSWIRE) -- Kane Biotech Inc. announces plans to expand its wound care and surgical portfolio with an antimicrobial hydrogel based on its best-in-class coactiv+ technology.
  • Use of the coactiv+TM technology in wound care products will complement the companys disruptive DispersinB wound care product development efforts whilst enabling the pursuit of the simpler 510(k) regulatory route and potentially quicker market access.
  • Kane estimates the US market for wound care hydrogels to be approximately US$200M.
  • We are committed to getting our coactiv+TM technology in the hands of wound care professionals and their patients as quickly as possible.

Terasaki Institute for Biomedical Innovation and Tetratherix™ Form Collaboration

Retrieved on: 
Tuesday, July 20, 2021
Physical sciences, Natural sciences, Biomaterials, Chemistry, Colloidal chemistry, Gels, Hydrogel, Water chemistry, Biocompatibility, Bio-ink, Draft:Terasaki Institute for Biomedical Innovation

LOS ANGELES, July 20, 2021 /PRNewswire/ -- The Terasaki Institute for Biomedical Innovation (TIBI) has formally signed a collaborative agreement with Tetratherix, a company which produces Tetramatrix, a synthetic injectable hydrogel currently being clinically tested in a variety of biomedical applications.

Key Points: 
  • LOS ANGELES, July 20, 2021 /PRNewswire/ -- The Terasaki Institute for Biomedical Innovation (TIBI) has formally signed a collaborative agreement with Tetratherix, a company which produces Tetramatrix, a synthetic injectable hydrogel currently being clinically tested in a variety of biomedical applications.
  • The unique and advantageous features of Tetramatrix offers the potential for further development into biocompatible, adhesive bioinks for deep tissue applications.
  • "This project will allow us to conduct world-class research in collaboration with TIBI to further expand our product pipeline in key therapeutic areas," said Ali Fathi, Tetratherix Founder and Director.
  • It is the hope that by optimizing the Tetramatrix bioinks, the TIBI researchers can help to translate them into viable biomedical applications.

Harvard Licenses Technology to Obatala Sciences to Advance Discovery in Obesity, Diabetes, and Cancer

Retrieved on: 
Wednesday, June 2, 2021
Stem cells, Biotechnology, Manufacturing, Diabetes, Health, General Health, Pharmaceutical, Oncology, Research, Engineering, Science, Colloidal chemistry, Gels, Hydrogel, Water chemistry, Accelerator, Harvard Office of Technology Development, Obatala Sciences, HARVARD OFFICE OF TECHNOLOGY DEVELOPMENT, OBATALA SCIENCES

Harvard Office of Technology Development and Obatala, which manufactures stem cell and hydrogel products to enable next-generation therapeutics discovery, announced the agreement today.

Key Points: 
  • Harvard Office of Technology Development and Obatala, which manufactures stem cell and hydrogel products to enable next-generation therapeutics discovery, announced the agreement today.
  • This ground-breaking technology provides a more accurate and dynamic model of human tissue in its diseased state compared to traditional two-dimensional culture.
  • The worldwide license agreement with Harvard enables Obatala to make the technology widely available for researchers use in drug discovery and R&D.
  • To further bridge the academic-industry development gap, Harvard OTD manages the Blavatnik Biomedical Accelerator and the Physical Sciences & Engineering Accelerator.

UroGen Pharma Announces June 2021 Conference Schedule

Retrieved on: 
Tuesday, May 25, 2021
Biotechnology, Pharmaceutical, Health, Oncology, Health sciences, Life sciences, Pharmacology, Biotechnology, Pharmaceutical industry, Colloidal chemistry, Gels, Hydrogel, Water chemistry, Modified-release dosage, Urology, Biopharmaceutical

A replay of each webcast will be available on the website for approximately 30 days.

Key Points: 
  • A replay of each webcast will be available on the website for approximately 30 days.
  • UroGen is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options.
  • UroGen has developed RTGel reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs.
  • UroGen is headquartered in Princeton, NJ with operations in Israel.

Contraline, Inc. Expands Board of Directors

Retrieved on: 
Thursday, May 6, 2021
MEN, Health, Consumer, Medical devices, Colloidal chemistry, Gels, Hydrogel, Water chemistry, Emerson, Medical device

Emerson brings to Contraline over 30 years of medical device industry experience.

Key Points: 
  • Emerson brings to Contraline over 30 years of medical device industry experience.
  • Mr. Emerson currently serves on the Board of Directors for SubioMed and Tepha Medical Devices, and has previously served on other boards of both public and private medical device companies.
  • The company is developing ADAM\xe2\x84\xa2, the world\xe2\x80\x99s first injectable hydrogel designed to provide long-lasting, non-permanent vas-occlusion for men.
  • The company was founded in 2015 by Kevin Eisenfrats and Dr. John Herr, and is headquartered in Charlottesville, Virginia.

UroGen Pharma to Report First Quarter 2021 Financial Results on Thursday, May 13, 2021

Retrieved on: 
Thursday, May 6, 2021
Biotechnology, Pharmaceutical, Health, Oncology, Colloidal chemistry, Gels, Hydrogel, Water chemistry

b"UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that it will report first quarter 2021 financial results on Thursday, May 13, 2021, prior to the open of the market.

Key Points: 
  • b"UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that it will report first quarter 2021 financial results on Thursday, May 13, 2021, prior to the open of the market.
  • The announcement will be followed by a live audio webcast and conference call at 8:30 AM Eastern Time.\nThe webcast will be made available on the Investors section of the Company\xe2\x80\x99s website at http://investors.urogen.com .
  • UroGen has developed RTGel\xe2\x84\xa2 reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs.
  • Visit www.urogen.com to learn more or follow us on Twitter, @UroGenPharma.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210506005066/en/\n"

DFRobot Open-Source Hardware Gravity Series Unleashes the Creativity for More Than 1 Million Developers Now

Retrieved on: 
Friday, March 19, 2021
Physical sciences, Chemistry, Natural sciences, Water pollution, Environmental science, Water chemistry, Water management, Water quality, Water supply, Turbidity, Environmental monitoring, Internet of things

SHANGHAI, March 19, 2021 /PRNewswire/ -- DFRobot Gravity series is a set of professional open-source hardware modules.

Key Points: 
  • SHANGHAI, March 19, 2021 /PRNewswire/ -- DFRobot Gravity series is a set of professional open-source hardware modules.
  • Till now, the Gravity series has been used by more than 1 million developers worldwide and used in a broad range of applications, like AI, environmental monitoring, IoT, smart homes, etc.
  • DFRobot Gravity series for environmental monitoring can measure water quality covering the pH value, dissolved oxygen, conductivity, and turbidity.
  • Gravity: KnowFlow Basic Kit: is designed for professional developers who want to monitor water quality and get real-time data.

Alafair Biosciences launches VersaWrap, a plant-based, non-collagen, bioresorbable interface for tendon and/or peripheral nerve

Retrieved on: 
Thursday, March 11, 2021
Branches of biology, Colloidal chemistry, Gels, Hydrogel, Water chemistry, Peripheral nervous system, Nerve

VersaWrap is the only hydrogel implant device indicated for the management of tendon and/or peripheral nerve tissues.

Key Points: 
  • VersaWrap is the only hydrogel implant device indicated for the management of tendon and/or peripheral nerve tissues.
  • VersaWrap is an ultrathin, sutureless, semi-permeable, hyaluronic-acid rich layer that encases injured or exposed tendon and/or peripheral nerves.
  • VersaWrap is indicated for the management of peripheral nerve injuries in which there has been no substantial loss of nerve tissue.
  • Alafair Biosciences is a privately held, commercial-stage medical device company focused on medical device development using its patented hydrogel technology.

Global Hydrogels Market Report 2020-2025 - Growing Focus on Baby Hygiene Products Spells Steady Growth Opportunities

Retrieved on: 
Tuesday, March 9, 2021
Physical sciences, Natural sciences, Chemistry, Gels, Colloidal chemistry, Hydrogel, Water chemistry, Self-healing hydrogels, Nanocomposite hydrogels

DUBLIN, March 9, 2021 /PRNewswire/ -- The "Hydrogels - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 9, 2021 /PRNewswire/ -- The "Hydrogels - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • The global market for Hydrogel is projected to reach US$15.3 billion by 2025, driven by their growing use in wound care products and drug delivery systems (DDS).
  • Superporous comb-type grafted hydrogels with fast response times; hybrid graft copolymers based self-assembling hydrogels; protein based hydrogels' and hybrid hydrogels are the emerging new future of smart hydrogel based biomaterials.
  • Some of the types of hydrogels development for drug delivery include DNA-hydrogels; supramolecular hydrogels; bio-inspired hydrogels; and multi-functional and stimuli-responsive hydrogels.

Global $15.3 Bn Hydrogels Market Trajectory & Analytics to 2025 - ResearchAndMarkets.com

Retrieved on: 
Friday, March 5, 2021
Pharmaceutical, Biotechnology, Physical sciences, Natural sciences, Chemistry, Gels, Colloidal chemistry, Hydrogel, Water chemistry, Self-healing hydrogels, Nanocomposite hydrogels

The "Hydrogels - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hydrogels - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • The global market for Hydrogel is projected to reach US$15.3 billion by 2025, driven by their growing use in wound care products and drug delivery systems (DDS).
  • Superporous comb-type grafted hydrogels with fast response times; hybrid graft copolymers based self-assembling hydrogels; protein based hydrogels' and hybrid hydrogels are the emerging new future of smart hydrogel based biomaterials.
  • Some of the types of hydrogels development for drug delivery include DNA-hydrogels; supramolecular hydrogels; bio-inspired hydrogels; and multi-functional and stimuli-responsive hydrogels.